Healthcare Industry News:  spinal cord injury 

Devices Drug Delivery Regenerative Medicine Neurology

 News Release - October 14, 2008

Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology

ROCKVILLE, Md., Oct. 14 (Healthcare Sales & Marketing Network) -- Neuralstem Inc., (Amex: CUR ) today announced that it has licensed the rights to three inventions from Cleveland Clinic pertaining to Targeted Spinal Cord Therapeutics Delivery. All three inventions were developed by Dr. Nicholas Boulis MD, formerly of Cleveland Clinic, now at Emory University.

"We are very pleased to have licensed-in these important delivery technology rights," said Neuralstem President & CEO, Richard Garr. "As we get ready to move into our expected human trial for ALS, we are focused on the optimal way to deliver our cell therapeutics to enhance the safety and efficacy of the treatments. Transplanting our cells directly into the spinal cord is a challenging but necessary part of trying to treat diseases of the spinal cord, not only in ALS, but in other spinal cord injuries and diseases." Garr went on to say, "The technology licensed today will help us to meet those goals."

Neuralstem will use this technology in its clinical trial for ALS (Amytrophic Lateral Sclerosis, or Lou Gehrig's disease). The company anticipates filing its IND (Investigational New Drug) application with the FDA for the ALS trial in the next few weeks, and hopes to start the trial early in 2009.

"Neuralstem is a second generation stem cell company," said Garr, "built not so much to do basic research and discovery, as to optimize our discovery of neural stem cells, and take them into the clinic and into patients. We believe that our technology answers many of the issues that have held the field back, and makes it possible to build a stem cell company with a true product focus."

The three inventions Neuralstem has licensed from Cleveland Clinic are: a Stabilized Platform and Microelectrode Recording Guidance Validation; a Floating Cannula for Spinal Cord Therapeutic Injection; and a Spinal Platform and Methods for Delivering a Therapeutic Agent to a Spinal Cord Target. All of these are for use in spinal cord surgery for the delivery of therapeutics. For a video on how the stem cells are anticipated to work once injected into the spinal cord, and other information on Neuralstem's technology go to: http://www.neuralstem.com/index.asp?pgid=14.

About Neuralstem

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia.

Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Paraplegia, Traumatic spinal cord injury and ALS. The company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis in rats with Ischemic Spastic Paraplegia, as reported in NEUROSCIENCE on June 29, 2007, in collaboration with researchers at University of California San Diego. The Company expects to file its first IND (Investigational New Drug) application with the FDA for ALS in the fall.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10- KSB for the year ended December 31, 2007 and the quarterly report on form 10-Q for the period ended June 30, 2008.


Source: Neuralstem

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.